A Comprehensive Review of Biomarker Endpoints in In Vivo Models of Parkinson’s Disease


Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.

View our webinar for a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.

Presenter

  • Robert Hodgson, PhD, Director, In Vivo Neuroscience, Integrated Drug Discovery, Charles River

Related Resources

Click the link below for the other webinar in the series: